Argenx SE
ARGX
株式のランク
#448
argenx SE, a biotechnology company established in Amsterdam, the Netherlands,... argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
株価
$875.26
時価総額
$54.72B
変化（1日）
6.01%
変化（1年）
3.04%
国
NL
取引 Argenx SE (ARGX)
カテゴリー
Healthcare
Argenx SE（ARGX）のP/E比率
October 2026 時点のP/E比率 TTM 30.33
Argenx SE の最新の財務報告および株価によると、現在の P/E (TTM) は 30.33 です。2023 年末時点での P/E は -73.46 でした。
Argenx SE の P/E 比率の履歴（2010 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 30.33 | -39.77% |
| 2024 | 50.36 | -168.56% |
| 2023 | -73.46 | 157.20% |
| 2022 | -28.56 | -38.42% |
| 2021 | -46.38 | 156.77% |
| 2020 | -18.06 | -40.99% |
| 2019 | -30.60 | -23.89% |
| 2018 | -40.21 | 1.91% |
| 2017 | -39.45 | 195.63% |
| 2016 | -13.35 | 28.85% |
| 2015 | -10.36 | 8.55% |
| 2014 | -9.54 | -34.89% |
| 2013 | -14.65 | 51.49% |
| 2012 | -9.67 | -64.98% |
| 2011 | -27.63 | 0.00% |
| 2010 | 0.00 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -5.10% |
US
|
|
| -28.36 | -193.50% |
US
|
|
| -24.57 | -181.00% |
AU
|
|
| - | - |
CH
|
|
| 17.49 | -42.34% |
BE
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。